Phenylbiguanide Derivative Modulating T Cell Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune diseases often fail to effectively suppress excessive immune responses, leading to unmanaged inflammation and tissue damage.
Innovation Solution
A pharmaceutical composition comprising a phenylbiguanide derivative compound, or its stereoisomer, derivative, solvate, or pharmaceutically acceptable salt, which inhibits the differentiation or proliferation of memory T cells and promotes effector T cell proliferation, thereby modulating the immune response to prevent or treat inflammatory and autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory and autoimmune diseases are used, then immune response suppression is attempted, but excessive immune responses are not effectively suppressed leading to unmanaged inflammation and tissue damage
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of biguanide derivatives (Formula 1) with specific substituents (R1-R6 groups, heterocyclic rings) to optimize immunosuppressive activity. The compound structure parameters are systematically varied to achieve enhanced suppression of memory T cell differentiation while maintaining safety, directly resolving the contradiction between effective immune suppression and harmful side effects
Solution Approach 2:
The patent employs composite materials by combining the phenylbiguanide derivative compound with pharmaceutically acceptable carriers, excipients, and adjuvants to create a pharmaceutical composition (Formula P). This composite approach enhances the therapeutic effect and bioavailability of the active compound, improving reliability of immune suppression while reducing harmful effects through optimized formulation
2Reliability
If N1-cyclicamine-N5-substituted phenylbiguanide derivative compound is used, then anticancer, anti-hhyperglycemic and lipid lowering effects are achieved, but the effect on immune response is not known
Solution Approach 1:
The patent applies preliminary action by conducting in vitro and in vivo studies before clinical application to establish the immunosuppressive effects of the compound. The patent describes preliminary experiments demonstrating inhibition of memory T cell differentiation and reduction of inflammatory cytokines, thereby filling the knowledge gap about immune response effects before therapeutic use
Solution Approach 2:
The patent implements feedback by using the compound's effects on memory T cells and inflammatory markers as indicators to optimize dosing and treatment protocols. The observed immunosuppressive effects provide feedback on compound activity, allowing adjustment of therapeutic parameters to maximize benefit while minimizing side effects
Data Source
AI summary
Provided are a pharmaceutical composition for preventing or treating inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof, the pharmaceutical composition including a compound represented by Formula 1, or a stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof, and a method using the pharmaceutical composition. The pharmaceutical composition and the method can be used to effectively prevent or treat inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof.